Diphenhydramine

Benadryl allergy capsules/liquid relieve labeled allergic runny nose, sneezing, itchy/watery eyes and nose/throat itching; selected capsules also relieve cold runny nose/sneezing. SleepMinis treats occasional sleeplessness, not chronic-insomnia disease management. Selected 2% diphenhydramine/0.1% zinc cream temporarily relieves minor skin pain/itch and dries poison-plant oozing; its combination ingredients and external route are explicit.

When oral therapy is impractical: uncomplicated immediate-type allergic conditions and blood/plasma reactions; anaphylaxis adjunct only after acute symptoms have been controlled with epinephrine/standard care; active motion-sickness treatment and selected parkinsonism circumstances. Do not infer routine OTC infant dosing or a first-line shock treatment from these historical injection indications.

Selected 25 mg capsules every 4–6 hours, maximum 6 doses in 24 hours: age ≥ 12 one or two (25–50 mg); 6–< 12 one (25 mg); below 6 do not use. Children’s 12.5 mg/5 mL liquid: ages 6–11 take 5–10 mL (12.5–25 mg) every 4–6 hours, maximum 6 doses; 2–5 only if doctor-directed; below 2 do not use. Its chart does not provide an adult liquid regimen. Use only its supplied measuring cup; do not transpose another liquid’s concentration.

SleepMinis 25 mg: age ≥ 12 two capsules (50 mg) at bedtime as needed; below 12 do not use. Consult for continuous sleeplessness > 2 weeks. Not every Unisom product contains diphenhydramine. Selected diphenhydramine 2%/zinc 0.1% cream: age ≥ 2 apply to the affected small area no more than 3–4 times daily; below 2 ask a doctor. Stop/review worsening, persistence > 7 days or rapid recurrence. Never combine either with another diphenhydramine product.

Selected 50 mg/mL injection: 10–50 mg IV at a rate generally≤25 mg/min or deep IM; 100 mg if required, maximum 400 mg/day. Individualize need/response. This is for supervised parenteral use when oral therapy is impractical; not intradermal, subcutaneous or a local anesthetic.

Other than premature infants/neonates: 5 mg/kg/day or 150 mg/m²/day, maximum 300 mg/day, divided into four doses; IV rate generally≤25 mg/min or deep IM. These are total daily doses, not per-dose 5 mg/kg. Pediatric safety precautions and exact product concentration/excipients require supervision; do not supply a neonate or OTC infant dose.

Selected labels give no fixed renal/hepatic adjustment algorithm; evaluate comorbidity and anticholinergic/sedative burden clinically. Allergy schedules have strict daily dose limits; do not double a missed dose. Sleep-aid dosing is at bedtime as needed, not an extra daytime catch-up. Topical exposure cannot be converted into an oral dose.

Selected injection: neonates/premature infants, nursing mothers, local-anesthetic use and hypersensitivity to diphenhydramine or chemically similar antihistamines. OTC labels instead give indication/product-specific do-not-use ages and duplicate-product prohibitions; oral pregnancy/breastfeeding labels require professional advice. Do not erase the injection’s explicit nursing contraindication or infer one universal age rule for every route.

Selected OTC and injection labels have no boxed warning. FDA high-dose warning, severe sedation/anticholinergic reactions and route-specific restrictions remain significant.

Sedation/dizziness, impaired coordination, dry mouth/nose/throat, blurred vision, GI symptoms and urinary retention are reported; injection experience also includes hypotension/palpitations, hypersensitivity and blood disorders. Overdose may stimulate or depress the CNS, with hallucinations, seizures, coma, cardiac problems or death. Collapse, inability to awaken, breathing trouble or seizure needs emergency care; contact Poison Help 1-800-222-1222. Never induce an improvised home reversal or use a published toxic dose as a safe threshold.

Alcohol, sedatives, hypnotics and tranquilizers add CNS depression; MAO inhibitors prolong/intensify anticholinergic effects. Review other anticholinergic medicines, glaucoma/urinary symptoms and total exposure. Current OTC labels prohibit combining with any other diphenhydramine product even if applied to skin. The selected cream includes zinc acetate; it is not an interchangeable oral preparation.

Allergy capsule self-use starts 6, the selected children’s liquid chart 6–11 with doctor-only ages 2–5 and no below 2 use; sleep product starts 12 and topical combination 2. Injection excludes premature infants/neonates and warns overdose may cause fatal hallucinations/convulsions. Older adults have greater sedative/hypotensive susceptibility; assess falls/confusion and alternative treatment rather than add routine nightly dosing.

OTC oral products ask for professional advice. Selected injection’s older pregnancy section notes inadequate controlled human studies and use only if clearly needed; its obsolete letter-category terminology is not a modern guarantee. It specifically contraindicates nursing mothers because of infant antihistamine risk. Discuss the exact route/product and alternatives; no universal safe infant exposure is claimed.

The selected labels supply no numeric organ-function dose algorithm. Injection label describes hepatic metabolism and some unchanged renal excretion but explicitly says detailed PK is unavailable. Assess organ disease, concurrent sedatives/anticholinergics and clinical response; do not invent a renal percentage reduction or a route-independent serum target.

Competes with histamine at effector-cell receptor sites; CNS penetration contributes to sedation and anticholinergic effects. Injectable onset is rapid, with wide distribution including CNS; drug is metabolized in liver and partly excreted unchanged in urine. Selected injection PI explicitly lacks detailed PK, so no universal half-life, protein-binding or renal-adjustment number is asserted. Topical activity and exposure depend on product/application.

Track benefit, sedation/coordination, paradoxical excitation, breathing, constipation/urination and duplicate exposures. Parenteral dosing requires rate/route verification and observation for BP, reaction and injection-site injury. Reassess sleep problems lasting > 2 weeks and topical symptoms > 7 days. No routine blood diphenhydramine level or universal ECG schedule is specified; suspected overdose needs urgent assessment.

Read ingredients of every sleep/allergy/cold/skin product; never combine diphenhydramine or give it to make a child sleep. Follow the exact dose/device and avoid alcohol/driving until effects are known. Injection is clinician-administered, not a home local anesthetic. Do not rely on it instead of epinephrine for anaphylaxis. Secure medicines away from children/teens; urgent overdose symptoms require emergency care.

Benadryl Allergy Liqui-Gels 25 mg diphenhydramine HCl per liquid-filled capsule; selected 24-capsule carton NDC 50580-228-24. Verify actual package and ingredient; not a stock claim.

Selected oral capsules 25 mg; children’s liquid 12.5 mg/5 mL; SleepMinis 25 mg capsules with 50 mg bedtime dose. Prescription injection 50 mg/mL, selected 1 mL institutional vial with benzethonium chloride; FDA ANDA 080817 Prescription. Taro topical combination diphenhydramine 2% plus zinc acetate 0.1%. OTC oral allergy, sleep and topical labels are monograph categories M 012, M 010 andM 017 respectively, not an assertion that every OTC brand has individual NDA approval.

Selected allergy capsules/liquid and cream 20–25°C; capsules avoid humidity/heat and protect light, liquid retain outer carton/protect light, cream follow seal/expiry. Injection 20–25°C, excursions 15–30°C, protect light in carton; single-dose institutional package is not child-resistant. SleepMinis selected Drug Facts do not state a numeric storage range; follow its actual package instead of importing another product’s range. Keep all products secure, never swallow cream or inject oral liquid.